Copyright
©The Author(s) 2025.
World J Psychiatry. Jan 19, 2025; 15(1): 98737
Published online Jan 19, 2025. doi: 10.5498/wjp.v15.i1.98737
Published online Jan 19, 2025. doi: 10.5498/wjp.v15.i1.98737
Table 1 Comparison of baseline data between the two groups
Group | Sex (female/male) | Age (years) | Tumor type, n (%) | |||
Bladder cancer | Prostate cancer | Kidney cancer | Ureter cancer | |||
Conventional group (n= 55) | 20/35 | 45.67 ± 6.51 | 28 (50.91) | 8 (14.55) | 15 (27.27) | 4 (7.27) |
Joint intervention group (n= 55) | 19/36 | 47.05 ± 5.92 | 29 (52.73) | 9 (16.36) | 12 (21.82) | 5 (9.09) |
χ2/t | 0.040 | -1.165 | 0.521 | |||
P value | 0.842 | 0.247 | 0.914 |
Table 2 Comparison of immune function indexes before and after intervention
Group | CD4+ (%) | CD8+ (%) | CD4+/CD8+ | |||
Before intervention | After intervention | Before intervention | After intervention | Before intervention | After intervention | |
Conventional group (n= 55) | 31.43 ± 1.62 | 36.10 ± 1.87a | 42.06 ± 1.87 | 40.35 ± 1.72a | 0.75 ± 0.05 | 0.90 ± 0.06a |
Joint intervention group (n= 55) | 31.16 ± 1.54 | 41.04 ± 2.30a | 42.52 ± 1.60 | 39.66 ± 1.52a | 0.73 ± 0.04 | 1.03 ± 0.08a |
t value | 0.919 | -12.331 | -1.403 | 2.259 | 1.772 | -11.054 |
P value | 0.360 | < 0.001 | 0.163 | 0.026 | 0.079 | < 0.001 |
Table 3 Comparison of quality of life questionnaire-core 30 scores before and after intervention
Group | Social function | Emotional function | Cognitive function | Body function | Role function | General health | ||||||
Before intervention | After intervention | Before intervention | After intervention | Before intervention | After intervention | Before intervention | After intervention | Before intervention | Before intervention | After intervention | Before intervention | |
Conventional group (n= 55) | 68.22 ± 3.50 | 73.13 ± 4.47a | 65.29 ± 3.50 | 70.13 ± 3.52a | 67.21 ± 3.55 | 69.11 ± 4.40a | 66.36 ± 5.75 | 68.73 ± 5.99a | 60.11 ± 3.50 | 67.51 ± 4.11a | 60.22 ± 4.06 | 66.25 ± 3.89a |
Joint intervention group (n= 55) | 68.73 ± 3.58 | 90.05 ± 5.11a | 66.00 ± 3.32 | 89.78 ± 4.77a | 66.56 ± 3.70 | 89.22 ± 4.30a | 65.62 ± 5.66 | 88.04 ± 5.94a | 59.24 ± 3.54 | 88.64 ± 6.39a | 59.49 ± 4.09 | 87.71 ± 4.70a |
t value | -0.754 | -18.491 | -1.091 | -24.603 | 0.947 | -24.247 | 0.685 | -16.975 | 1.300 | -20.625 | 0.937 | -26.068 |
P value | 0.453 | < 0.001 | 0.278 | < 0.001 | 0.346 | 0.495 | < 0.001 | 0.196 | < 0.001 | 0.351 | < 0.001 |
Table 4 Comparison of cancer fatigue scale scores before and after intervention
Group | Body fatigue | Emotional fatigue | Cognitive fatigue | CFS total score | ||||
Before intervention | After intervention | Before intervention | After intervention | Before intervention | After intervention | Before intervention | After intervention | |
Conventional group (n = 55) | 13.91 ± 1.28 | 12.96 ± 1.23 | 10.95 ± 1.66 | 10.22 ± 1.37c | 6.96 ± 1.95 | 6.02 ± 1.55b | 31.82 ± 2.67 | 29.20 ± 2.12c |
Joint intervention group (n = 55) | 14.09 ± 1.42 | 11.13 ± 1.07a | 10.82 ± 1.76 | 9.13 ± 1.25b | 6.89 ± 1.80 | 5.29 ± 1.24c | 31.80 ± 2.67 | 25.76 ± 2.19c |
t value | -0.706 | 8.339 | 0.390 | 4.365 | 0.203 | 2.720 | 0.036 | 8.975 |
P value | 0.482 | < 0.001 | 0.698 | < 0.001 | 0.840 | 0.008 | 0.971 | < 0.001 |
Table 5 Comparison of adverse reactions during the intervention period, n (%)
Group | Urodynia | Hematuria | Dysuria | Frequent and urgent urination | Total incidence (%) |
Conventional group (n = 55) | 7 (12.73) | 5 (9.01) | 4 (5.33) | 6 (10.91) | 22 (40.00) |
Joint intervention group (n = 55) | 4 (5.33) | 2 (3.64) | 2 (3.64) | 3 (5.45) | 11 (20.00) |
χ2 | 5.238 | ||||
P value | 0.022 |
Table 6 Comparison of nursing satisfaction, n (%)
Group | Very satisfied | Satisfied | Dissatisfied | Satisfaction (%) |
Conventional group (n = 55) | 22 (40.00) | 20 (36.36) | 13 (23.64) | 42 (76.36) |
Joint intervention group (n = 55) | 32 (58.18) | 19 (34.55) | 4 (7.27) | 51 (92.73) |
χ2 | 5.636 | |||
P value | 0.018 |
- Citation: Liu J, Guo YP, Lu YM, Wang BL. Clinical value of combining epirubicin with mindfulness intervention in patients with urinary system tumors and depression. World J Psychiatry 2025; 15(1): 98737
- URL: https://www.wjgnet.com/2220-3206/full/v15/i1/98737.htm
- DOI: https://dx.doi.org/10.5498/wjp.v15.i1.98737